Elahere (mirvetuximab soravtansina) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento
swki.me/vRkH9OT7
#infarmed #medicamentos #financiamentopublico #elahere
swki.me/vRkH9OT7
#infarmed #medicamentos #financiamentopublico #elahere
September 23, 2026 at 1:58 PM
Elahere (mirvetuximab soravtansina) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento
swki.me/vRkH9OT7
#infarmed #medicamentos #financiamentopublico #elahere
swki.me/vRkH9OT7
#infarmed #medicamentos #financiamentopublico #elahere
武田薬品がELAHERE（ミルベツキシマブ ソラブタンシン）の国内承認を発表──葉酸受容体α陽性の卵巣がんに対する国内初のADC、MIRASOL試験など根拠を整理
stellanews.life/technology/1... #ELAHERE #FRα
stellanews.life/technology/1... #ELAHERE #FRα
武田薬品がELAHERE（ミルベツキシマブ ソラブタンシン）の国内承認を発表──葉酸受容体α陽性の卵巣がんに対する国内初のADC、MIRASOL試験など根拠を整理
武田薬品工業は2026年9月16日、ミルベツキシマブ ソラブタンシン（遺伝子組換え）「ELAHERE」の国内製造販売承認取得を発表した。葉酸受容体α陽性の白金製剤抵抗性再発卵巣がんを対象とし、根拠となったMIRASOL試験・SORAYA試験・国内第1/2相試験の概要と安全性を整理する。
stellanews.life
September 16, 2026 at 10:27 PM
武田薬品がELAHERE（ミルベツキシマブ ソラブタンシン）の国内承認を発表──葉酸受容体α陽性の卵巣がんに対する国内初のADC、MIRASOL試験など根拠を整理
stellanews.life/technology/1... #ELAHERE #FRα
stellanews.life/technology/1... #ELAHERE #FRα
【葉酸受容体α陽性の再発卵巣がん、国内初のADCが承認】
武田のELAHERE（ミルベツキシマブ ソラブタンシン）。白金抵抗性。根拠はMIRASOLのPFSとOS。国内第1/2相でも国際試験と一致した。
武田のELAHERE（ミルベツキシマブ ソラブタンシン）。白金抵抗性。根拠はMIRASOLのPFSとOS。国内第1/2相でも国際試験と一致した。
September 16, 2026 at 10:27 PM
【葉酸受容体α陽性の再発卵巣がん、国内初のADCが承認】
武田のELAHERE（ミルベツキシマブ ソラブタンシン）。白金抵抗性。根拠はMIRASOLのPFSとOS。国内第1/2相でも国際試験と一致した。
武田のELAHERE（ミルベツキシマブ ソラブタンシン）。白金抵抗性。根拠はMIRASOLのPFSとOS。国内第1/2相でも国際試験と一致した。
2/2
Liek Elahere jej síce účinkuje už päť mesiacov, no stojí takmer 9-tisíc eur na tri týždne a na Slovensku nie je kategorizovaný, čiže poisťovňa ho štandardne neuhrádza. (N)
Liek Elahere jej síce účinkuje už päť mesiacov, no stojí takmer 9-tisíc eur na tri týždne a na Slovensku nie je kategorizovaný, čiže poisťovňa ho štandardne neuhrádza. (N)
August 22, 2026 at 3:45 AM
2/2
Liek Elahere jej síce účinkuje už päť mesiacov, no stojí takmer 9-tisíc eur na tri týždne a na Slovensku nie je kategorizovaný, čiže poisťovňa ho štandardne neuhrádza. (N)
Liek Elahere jej síce účinkuje už päť mesiacov, no stojí takmer 9-tisíc eur na tri týždne a na Slovensku nie je kategorizovaný, čiže poisťovňa ho štandardne neuhrádza. (N)
▶️ Doc. Irina Dulebová už 6 rokov bojuje s rakovinou. Nová cielená liečba ELAHERE jej priniesla nádej a zlepšenie, no na Slovensku nie je hradená. Pomôžme jej udržať liečbu. donio.sk/pomozme-irin...
Prečítajte si príbeh Iriny a Alexandra Dulebovcov a pomôžte, ak môžete. dennikn.sk/5514572/irin...
Prečítajte si príbeh Iriny a Alexandra Dulebovcov a pomôžte, ak môžete. dennikn.sk/5514572/irin...
Pomôžme Irine financovať onkologickú liečbu, ktorá jej prináša novú nádej
Doc. Irina Dulebová z UK už 6 rokov bojuje s rakovinou. Nová cielená liečba ELAHERE jej priniesla nádej a zlepšenie, no na Slovensku nie je hradená. Pomôžme jej udržať liečbu, aby mohla ďalej učiť a b...
donio.sk
August 21, 2026 at 10:42 AM
▶️ Doc. Irina Dulebová už 6 rokov bojuje s rakovinou. Nová cielená liečba ELAHERE jej priniesla nádej a zlepšenie, no na Slovensku nie je hradená. Pomôžme jej udržať liečbu. donio.sk/pomozme-irin...
Prečítajte si príbeh Iriny a Alexandra Dulebovcov a pomôžte, ak môžete. dennikn.sk/5514572/irin...
Prečítajte si príbeh Iriny a Alexandra Dulebovcov a pomôžte, ak môžete. dennikn.sk/5514572/irin...
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it in Canada. share.nwmd.social/s/JJbcgtm8
Canadians deserve timely access to cancer treatments
share.nwmd.social
August 13, 2026 at 11:56 PM
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it in Canada. share.nwmd.social/s/JJbcgtm8
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/e6UaIP0s Dickering around while women suffer and die while a cure NOW exists! 😖
CANADIANS DESERVE ACCESS TO INNOVATIVE OVARIAN CANCER TREATMENTS NOW
share.nwmd.social
August 13, 2026 at 3:09 PM
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/e6UaIP0s Dickering around while women suffer and die while a cure NOW exists! 😖
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/SowD0vrG
CANADIANS DESERVE ACCESS TO INNOVATIVE OVARIAN CANCER TREATMENTS NOW
share.nwmd.social
July 31, 2026 at 12:46 AM
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/SowD0vrG
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/ENtrrary
#OvarianCancer #WomensHealth
#OvarianCancer #WomensHealth
Canadians deserve timely access to cancer treatments.
share.nwmd.social
July 30, 2026 at 7:23 PM
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/ENtrrary
#OvarianCancer #WomensHealth
#OvarianCancer #WomensHealth
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/lY23EcoW
Canadians deserve timely access to cancer treatments
share.nwmd.social
July 19, 2026 at 9:08 AM
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/lY23EcoW
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/K6teM3ks
Canadians deserve timely access to cancer treatments
share.nwmd.social
July 17, 2026 at 11:28 PM
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/K6teM3ks
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/JQCmOHnL
Canadians deserve timely access to cancer treatments
share.nwmd.social
July 17, 2026 at 1:51 PM
ELAHERE is the first new treatment for platinum-resistant ovarian cancer in more than a decade. Please restart negotiations and make it available to those who need it. share.nwmd.social/s/JQCmOHnL
AbbVie ($ABBV) shows durable MRD control in 9yr venetoclax CLL14 - fixed regimen cuts cost vs continuous BTKi; NICE greenlight for Elahere plus Apogee buy bolster pipeline. Expect +25% rerate. Use @bluestocks.app #finsky
June 21, 2026 at 12:05 PM
AbbVie ($ABBV) shows durable MRD control in 9yr venetoclax CLL14 - fixed regimen cuts cost vs continuous BTKi; NICE greenlight for Elahere plus Apogee buy bolster pipeline. Expect +25% rerate. Use @bluestocks.app #finsky
Ophthopedia Update: ‘Be intentional, aggressive’ with ocular effects of cancer drugs: PHOENIX — Mirvetuximab, an antibody drug conjugate for the treatment of certain types of cancer, can lead to adverse ocular events in the early weeks of treatment, according to a poster here.
Across four cases of…
Across four cases of…
‘Be intentional, aggressive’ with ocular effects of cancer drugs
PHOENIX — Mirvetuximab, an antibody drug conjugate for the treatment of certain types of cancer, can lead to adverse ocular events in the early weeks of treatment, according to a poster here.
Across four cases of folate receptor-alpha positive, platinum-resistant epithelial ovarian and fallopian tube cancer, three patients developed corneal subepithelial microcysts in the early weeks of treatment with Elahere (mirvetuximab, AbbVie).
Other findings included superficial punctate keratitis, epithelial ridge, stromal haze and posterior subcapsular cataract.
“For most, the initial presentation was in
dlvr.it
June 19, 2026 at 2:48 PM
Ophthopedia Update: ‘Be intentional, aggressive’ with ocular effects of cancer drugs: PHOENIX — Mirvetuximab, an antibody drug conjugate for the treatment of certain types of cancer, can lead to adverse ocular events in the early weeks of treatment, according to a poster here.
Across four cases of…
Across four cases of…
AbbVie and $ABBV: ADC approvals (CD123) plus Elahere HTA wins validate oncology thesis; clinical benefit is clear but NHS pricing will cap upside-20% rerate. https://www.reuters.com/legal/litigation/british-drug-cost-watchdog-recommends-use-abbvies-ovarian-cancer-therapy-2026-06-03/
June 14, 2026 at 1:04 PM
AbbVie and $ABBV: ADC approvals (CD123) plus Elahere HTA wins validate oncology thesis; clinical benefit is clear but NHS pricing will cap upside-20% rerate. https://www.reuters.com/legal/litigation/british-drug-cost-watchdog-recommends-use-abbvies-ovarian-cancer-therapy-2026-06-03/
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
Ovarian cancer drug approved for NHS use will prolong lives
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
tcnv.link
June 11, 2026 at 1:13 PM
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
Ovarian cancer drug approved for NHS use will prolong lives
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
Ovarian cancer drug approved for NHS use will prolong lives
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
fllics.com
June 11, 2026 at 12:06 PM
Ovarian cancer drug approved for NHS use will prolong lives
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
NICE recommendation for mirvetuximab soravtansine (Elahere) approved for folate-receptor-alpha positive platinum-resistant ovarian cancer; clinical trial showed 3.9-month median survival extension and 1.6…
https://goodlede.com/story/nhsrollsoutlifeextendingdrugforhundredsofwomenwithovariancan
https://goodlede.com/story/nhsrollsoutlifeextendingdrugforhundredsofwomenwithovariancan
NHS Rolls Out Life-Extending Drug for Hundreds of Women with Ovarian Cancer
Verified by Goodlede: what backs this story and what it doesn't prove.
goodlede.com
June 9, 2026 at 2:30 PM
NICE recommendation for mirvetuximab soravtansine (Elahere) approved for folate-receptor-alpha positive platinum-resistant ovarian cancer; clinical trial showed 3.9-month median survival extension and 1.6…
https://goodlede.com/story/nhsrollsoutlifeextendingdrugforhundredsofwomenwithovariancan
https://goodlede.com/story/nhsrollsoutlifeextendingdrugforhundredsofwomenwithovariancan
Feed: "Talker"
By: Talker News on Friday, June 5, 2026
By: Talker News on Friday, June 5, 2026
New ovarian cancer treatment dubbed ‘biological missile’ approved
The treatment, Elahere, is only approved for ovarian cancer.
talker.news
June 6, 2026 at 2:19 PM
Feed: "Talker"
By: Talker News on Friday, June 5, 2026
By: Talker News on Friday, June 5, 2026
